The gene product of the BCR-ABL1 fusion gene is a kinase with a higher activity compared to the activity of the native ABL1 kinase. The analysis of the protein structure...
Latest videos
Onkoview 2015
BCR-ABL1 and the Philadelphia chromosome – Part 4: Therapy of tumors with BCR-ABL1 fusion proteins
The specific BCR-ABL1 inhibitor molecule Glivec was the first anti-cancer drug to be developed against a tumor-specific protein. Glivec binds to the catalytic domain of...
The MAPK pathway is dysregulated in more than 50 % of all human tumors. The pathway starts with the activation of a receptor tyrosine kinase, which transmits the signal...
The phoshatidylinositol-3 kinase (PI3K) can be activated by binding directly or via the protein IRS-1 to the activated receptor tyrosine kinase. Alternatively, PI3K can...
The second messenger PIP3 formed by PI3K can be hydrolyzed to PIP2 by the phosphatase PTEN. PIP2 can be hydrolyzed to diacyl glycerol (DAG) and inositol trisphosphate...
The phosphatase PTEN dephosphorylates PIP3 to PIP2, which can then be hydrolyzed to DAG and IP3. In addition, PTEN performs many other functions by binding to and...
